Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

100866

	registered interest
	date	24/10/2014
	answering body	Department for Education
	answering dept id	60
	answering dept short name	Education
	answering dept sort name	Education
	hansard heading	Academies
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Education, how many new school applications have been processed by regional school commissioners; how many such applications were (a) approved and (b) refused; and what the reasons for such approval or refusal were in each case.
	tabling member constituency	Gateshead
	tabling member printed	Ian Mearns
	uin	211862
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The regional schools commissioners (RSCs) have been involved in nine applications for new academies under the academy presumption (section 6A of the Education and Inspections Act 2006). RSCs do not make the decision about whether a new school is needed or not. This decision lies with the relevant local authority, and arises from the basic need for more pupil places. The RSCs’ role is limited to deciding who would be the best proposer to establish the new school.</p><p>In six cases the RSC approved the proposer recommended by the local authority. In three cases a different proposer was approved. In each case this decision was taken based on an assessment of the capacity, capability and performance of all proposers.</p><p>RSCs do not currently make decisions about free school applications.</p> answering member constituency Crewe and Nantwich answering member printed Mr Edward Timpson question first answered 29/10/2014 17:54:54 answering member 1605 label Biography information for Edward Timpson
	tabling member	4000 label Biography information for Ian Mearns

100423

	registered interest
	date	22/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Alcoholic Drinks: Labelling
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the effect of mandatory labelling on all alcoholic products on the incidence of foetal alcohol spectrum disorders; and if he will make a statement.
	tabling member constituency	Hazel Grove
	tabling member printed	Sir Andrew Stunell
	uin	211414
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The Government is committed to improving the labelling of alcoholic drinks, including a warning to avoid alcohol for women who are pregnant or trying to conceive. It is not mandatory to include warnings on drinking in pregnancy on labels. However, as part of the Public Health Responsibility Deal, alcohol retailers and producers have a responsibility to help raise this awareness and have committed to putting an agreed warning or a pregnancy warning logo on 80% of labels on bottles and cans.</p><p> </p><p>An independent market survey has been carried out which we expect to be published shortly.</p><p> </p><p> </p><p> </p><p>The evidence is that health information on labels should not be considered a standalone measure, but part of broader efforts to raise consumer awareness and education on the health risks linked to alcohol consumption.</p><p> </p><p> </p><p> </p><p>This is supported by research commissioned by the Department in 2005 to review the evidence around the effectiveness of alcohol harm reduction communications and related campaigns.</p><p> </p><p><strong> </strong></p><p> </p><p>The Chief Medical Officer is currently overseeing a United Kingdom-wide review of all alcohol guidelines so that people can make informed choices about their drinking at all stages of their lives.</p><p> </p><p> </p><p> </p><p>The review will specifically include consideration of health risks for women from alcohol consumption. We expect to be able to consult on new draft guidelines by summer 2015.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 29/10/2014 17:00:37 answering member 3918 label Biography information for Jane Ellison
	tabling member	445 label Biography information for Lord Stunell

100391

	registered interest
	date	22/10/2014
	answering body	Foreign and Commonwealth Office
	answering dept id	16
	answering dept short name	Foreign and Commonwealth Office
	answering dept sort name	Foreign and Commonwealth Office
	hansard heading	Antisemitism
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Foreign and Commonwealth Affairs, what assessment he has made of trends in the level of anti-semitism in Europe; what recent discussions he has had on anti-semitism with his European counterparts; and if he will make a statement.
	tabling member constituency	Harrow West
	tabling member printed	Mr Gareth Thomas
	uin	211509
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The British Government is committed to combating anti-Semitism wherever it is found and supports the efforts of EU partners to tackle racism in all its forms.</p><p>The November 2013 report of the European Union Agency for Fundamental Rights (FRA), indicated that two-thirds of people identifying themselves as Jewish across eight EU Member States considered anti-Semitism to be a problem in their country. As current Chair of the International Holocaust Remembrance Alliance (IHRA), the UK will be discussing this issue at the IHRA's Plenary Meetings in Manchester in December.</p><p>The Foreign and Commonwealth Office also works very closely with the UK Member of the European Commission against Racism and Intolerance (ECRI), which provides expert advice on tackling anti-Semitism to other EU Member States.</p><p>The British Government will be represented at a senior level at the tenth anniversary of the Organization for Security and Cooperation in Europe (OSCE) Conference and Declaration on Anti-Semitism, being held in Berlin on 13 November.</p> answering member constituency Aylesbury answering member printed Mr David Lidington question first answered 29/10/2014 15:50:24 answering member 15 label Biography information for Sir David Lidington
	tabling member	177 label Biography information for Gareth Thomas

100604

	registered interest
	date	23/10/2014
	answering body	Department for Business, Innovation and Skills
	answering dept id	26
	answering dept short name	Business, Innovation and Skills
	answering dept sort name	Business, Innovation and Skills
	hansard heading	Apprentices
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government how many (1) 16 year-olds, (2) 17 year-olds, and (3) 18 year-olds started apprenticeships in the academic years 2012–13 and 2013–14 in England.
	tabling member printed	Lord Smith of Clifton
	uin	HL2335
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>Table 1 shows the number of apprenticeship starts for 16, 17 and 18 year olds in 2012/13 and provisional full year apprenticeship starts for the same ages in 2013/14. Provisional data are subject to change and should not be directly compared with data from earlier academic years.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong>Table 1: Apprenticeship starts by age (2012/13 and 2013/14 provisional full year)</strong></p><p> </p><table><tbody><tr><td><p><strong> </strong></p></td><td><p><strong>2012/13</strong></p></td><td><p><strong>2013/14</strong></p></td></tr><tr><td><p> </p></td><td><p> </p></td><td><p>Full year</p></td></tr><tr><td><p>Age</p></td><td><p>Full year</p></td><td><p>(provisional)</p></td></tr><tr><td><p>16</p></td><td><p>25,080</p></td><td><p>25,170</p></td></tr><tr><td><p>17</p></td><td><p>35,810</p></td><td><p>38,320</p></td></tr><tr><td><p>18</p></td><td><p>53,430</p></td><td><p>54,140</p></td></tr></tbody></table><p> </p><p>Notes</p><p> </p><p>1) Volumes are rounded to the nearest 10.</p><p> </p><p>2) Age is calculated based on age at start of the programme rather than based on 31 August.</p><p> </p><p>3) Provisional data are subject to change and should not be directly compared with data from earlier academic years.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member printed Baroness Neville-Rolfe question first answered 29/10/2014 17:05:23 answering member 4284 label Biography information for Baroness Neville-Rolfe
	tabling member	3144 label Biography information for Lord Smith of Clifton

92222

	registered interest
	date	26/09/2014
	answering body	Foreign and Commonwealth Office
	answering dept id	16
	answering dept short name	Foreign and Commonwealth Office
	answering dept sort name	Foreign and Commonwealth Office
	hansard heading	Arctic Council
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Foreign and Commonwealth Affairs, how many officials there were in the UK delegation to the 2013 Arctic Council Ministerial meeting in Kiruna, Sweden; and what the (a) title of position and (b) grade was of each such official.
	tabling member constituency	Moray
	tabling member printed	Angus Robertson
	uin	209769
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The UK continues to support the Nigerian authorities in trying to establish the location of the abducted schoolgirls. We provide surveillance assets, in the form of RAF Tornados, to assist in the search and expertise to assist in intelligence analysis. The resolve of Nigeria, the UK and international community to continue the search remains strong.</p><p>On 3 September I led the UK delegation to the ministerial meeting in Abuja on security in Nigeria, attended by Nigeria’s neighbours and international partners. I emphasised the crucial importance of regional coordination to locating the girls taken from Chibok and to defeating Boko Haram.</p> answering member constituency Rochford and Southend East answering member printed James Duddridge question first answered 29/10/2014 14:51:14 answering member 1559 label Biography information for Sir James Duddridge
	tabling member	1433 label Biography information for Angus Robertson

92232

	registered interest
	date	26/09/2014
	answering body	Foreign and Commonwealth Office
	answering dept id	16
	answering dept short name	Foreign and Commonwealth Office
	answering dept sort name	Foreign and Commonwealth Office
	hansard heading	Armed Conflict: Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Foreign and Commonwealth Affairs, what steps he is taking with African Union governments to end the recruitment of children into the national armed forces of countries where this practice takes place; and if he will make a statement.
	tabling member constituency	Brighton, Kemptown
	tabling member printed	Simon Kirby
	uin	209687
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The UK Government is committed to helping countries end the recruitment and use of children in conflict. <br> <br>During the United Nations General Assembly in New York, I hosted a Ministerial roundtable, chaired by the UN Special Representative of the Secretary General for Children and Armed Conflict, Ms Leila Zerrougui. The event brought together Afghanistan, Burma, Chad, Liberia, Sierra Leone, Somalia, South Sudan, Sudan, Yemen and African Union (AU) Commissioner for Peace and Security, Mr Smail Chergui.</p><p>The meeting looked at ways to end the recruitment and use of children in conflict by government forces, particularly through the implementation of UN Action Plans. It allowed countries that have successfully ended this practice to share lessons with those who are working towards this goal.</p><p>The roundtable built on an event during the End Sexual Violence in Conflict Summit in London in June, led by my Honourable friend Mark Simmonds MP, where Ministers from Sierra Leone, Democratic Republic of Congo and Somalia underlined their commitment to ending the recruitment and use of children in armed conflict.</p><p>The UK is also the majority funder of a Child Protection Adviser at the AU. This post is designed to ensure child protection policies are mainstreamed in AU peace enforcement operations on the continent.</p> answering member constituency Bournemouth East answering member printed Mr Tobias Ellwood question first answered 29/10/2014 14:43:10 answering member 1487 label Biography information for Mr Tobias Ellwood
	tabling member	3929 label Biography information for Simon Kirby

100877

	registered interest
	date	24/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Asthma
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what estimate he has made of the cost to the NHS of treating asthma in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211847
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table sets out expenditure on asthma from 2008-09 to 2012-13<sup>1 </sup></p><p> </p><p> </p><p> </p><p> </p><p> </p><table><tbody><tr><td colspan="5"><p>Expenditure (£ billion)</p></td></tr><tr><td><p>2008-09</p></td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td></tr><tr><td><p>0.87</p></td><td><p>0.91</p></td><td><p>0.99</p></td><td><p>1.01</p></td><td><p>1.05</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p> </p><p> </p><p><sup>1</sup> Aggregate primary care trust (PCT) expenditure on own population from programme budgeting collection. Programme budgeting is an annual collection of expenditure on healthcare conditions by NHS Commissioners. Programme budgeting figures are only estimates.</p><p> </p><p> </p><p> </p><p>It should be noted that this does not include expenditure on primary care appointments which is included as a separate category. Other areas of expenditure such as Outpatients and Community Care cannot always be allocated to sub-categories so some expenditure on asthma may be included in ‘Problems of the Respiratory System – Other’ or ‘Other - Miscellaneous’.</p><p> </p><p><strong> </strong></p><p> </p><p>Further notes on interpretation of data:</p><p> </p><p>- Expenditure data are calculated from programme budgeting returns for 2003-04 to 2012-13. Programme budgeting returns are based on a subset of PCT accounts data and represent a subset of overall NHS expenditure data.</p><p> </p><p> </p><p> </p><p>- Calculating programme budgeting data is complex and not all healthcare activity or services can be classified directly to a programme budgeting category or care setting. When it is not possible to reasonably estimate a programme budgeting category, expenditure is classified as ‘Other’. Expenditure on General Medical Services and Personal Medical Services cannot be reasonably estimated at disease specific level, and is separately identified as a subcategory of ‘Other’ expenditure.</p><p> </p><p> </p><p> </p><p>- The allocation of expenditure to programme budgeting subcategories is not always straightforward, and subcategory level data should therefore be used with caution.</p><p> </p><p> </p><p> </p><p>- In order to improve data quality, continual refinements have been made to the programme budgeting data calculation methodology since the first collection in 2003-04. The underlying data which support programme budgeting data are also subject to yearly changes. Programme budgeting data cannot be used to analyse changes in investment in specific service areas between years. Users of the data should note that significant changes to the data calculation methodology were introduced in 2010-11.</p><p> </p><p> </p><p> </p><p>- Figures for years 2003-04 to 2009-10 are calculated using provider costs as a basis. Figures for 2010-11 to 2012-13 are calculated using price paid for specific activities and services purchased from healthcare providers. PCTs follow standard guidance, procedures and mappings when calculating programme budgeting data.</p><p> </p><p> </p><p> </p><p>- PCT figures used to calculate 2010-11 data differ from those previously published in the 2010-11 programme budgeting benchmarking spreadsheet. This is due to the correction of errors identified for five PCTs for this year.</p><p> </p><p> </p><p> </p><p>- Aggregate PCT data supersede previously published England level programme budgeting data. England level data incorporated estimates of expenditure on healthcare conditions for the Department of Health, strategic health authorities and special health authorities. England level data is no longer published this data as aggregate PCT figures provide a more accurate and meaningful representation of the breakdown of NHS expenditure by healthcare condition.</p><p> </p><p> </p><p> </p><p>- For 2003-04, figures are based on PCT net expenditure. For 2004-05 onwards, figures are based on PCT spend on own population. This is calculated by adjusting net expenditure to add back expenditure funded from sources outside the NHS and to deduct expenditure on other PCT populations incurred through lead commissioning arrangements.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 29/10/2014 15:06:29 answering member 1439 label Biography information for Norman Lamb
	tabling member	4026 label Biography information for Liz Kendall

100887

	registered interest
	date	24/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Asthma
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much public funding was allocated to research into asthma in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211918
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

100876

	registered interest
	date	24/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Asthma: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much has been spent on the prescription of asthma drugs in the NHS in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211846
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>Information on National Health Service expenditure on drugs for the treatment of asthma in primary and secondary care is in the table.</p><p> </p><p><strong> </strong></p><p> </p><p>Drugs for the treatment of osteoporosis have been defined as those included in the following British National Formulary sections:</p><p> </p><p>3.1.1 Adrenoceptor agonists</p><p> </p><p>3.1.2 Antimuscarinic bronchodilators</p><p> </p><p>3.1.3 Theophylline</p><p> </p><p>3.2 Corticosteroids</p><p> </p><p>3.3.1 Cromoglicate and related therapy</p><p> </p><p>3.3.2 Leukotriene receptor antagonists</p><p> </p><p>3.4.2 Allergen immunotherapy (omalizumab only)</p><p> </p><p> </p><p> </p><table><tbody><tr><td colspan="11"><p>Cost of drugs for the treatment of asthma, England<sup>1</sup></p></td></tr><tr><td rowspan="2"><p>Drug name</p></td><td colspan="5"><p>Primary Care (£ millions)</p></td><td colspan="5"><p>Secondary Care (£ millions)</p></td></tr><tr><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td></tr><tr><td><p>Aclidinium Bromide</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>0.02</p></td><td><p>1.62</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>0.00</p></td><td><p>0.03</p></td></tr><tr><td><p>Aminophylline</p></td><td><p>1.25</p></td><td><p>1.18</p></td><td><p>1.12</p></td><td><p>1.08</p></td><td><p>1.05</p></td><td><p>0.30</p></td><td><p>0.29</p></td><td><p>0.21</p></td><td><p>0.23</p></td><td><p>0.22</p></td></tr><tr><td><p>Beclometasone Dipropionate</p></td><td><p>84.26</p></td><td><p>87.72</p></td><td><p>90.30</p></td><td><p>97.56</p></td><td><p>102.39</p></td><td><p>1.62</p></td><td><p>1.53</p></td><td><p>1.41</p></td><td><p>1.49</p></td><td><p>1.42</p></td></tr><tr><td><p>Budesonide</p></td><td><p>140.35</p></td><td><p>149.03</p></td><td><p>158.82</p></td><td><p>169.14</p></td><td><p>177.00</p></td><td><p>1.29</p></td><td><p>1.14</p></td><td><p>1.14</p></td><td><p>1.27</p></td><td><p>1.41</p></td></tr><tr><td><p>Budesonide/ Formoterol</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>2.75</p></td><td><p>2.94</p></td><td><p>2.89</p></td><td><p>3.10</p></td><td><p>3.29</p></td></tr><tr><td><p>Ciclesonide</p></td><td><p>0.84</p></td><td><p>0.95</p></td><td><p>1.03</p></td><td><p>1.12</p></td><td><p>1.25</p></td><td><p>0.01</p></td><td><p>0.02</p></td><td><p>0.02</p></td><td><p>0.02</p></td><td><p>0.03</p></td></tr><tr><td><p>Fluticasone</p></td><td><p>366.24</p></td><td><p>380.56</p></td><td><p>387.89</p></td><td><p>392.95</p></td><td><p>396.10</p></td><td><p>1.00</p></td><td><p>0.93</p></td><td><p>0.91</p></td><td><p>1.00</p></td><td><p>0.99</p></td></tr><tr><td><p>Fluticasone/ Salmeterol</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>11.46</p></td><td><p>11.56</p></td><td><p>10.69</p></td><td><p>10.82</p></td><td><p>10.48</p></td></tr><tr><td><p>Formoterol Fumarate</p></td><td><p>5.18</p></td><td><p>4.87</p></td><td><p>4.68</p></td><td><p>4.85</p></td><td><p>4.93</p></td><td><p>0.10</p></td><td><p>0.08</p></td><td><p>0.07</p></td><td><p>0.06</p></td><td><p>0.06</p></td></tr><tr><td><p>Glycopyrronium Bromide</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>0.01</p></td><td><p>2.30</p></td><td><p>0.58</p></td><td><p>0.62</p></td><td><p>0.70</p></td><td><p>0.79</p></td><td><p>1.00</p></td></tr><tr><td><p>Indacaterol Maleate</p></td><td><p>-</p></td><td><p>0.04</p></td><td><p>0.30</p></td><td><p>0.92</p></td><td><p>1.47</p></td><td><p>-</p></td><td><p>0.00</p></td><td><p>0.00</p></td><td><p>0.02</p></td><td><p>0.04</p></td></tr><tr><td><p>Ipratropium Bromide</p></td><td><p>16.15</p></td><td><p>15.02</p></td><td><p>13.74</p></td><td><p>10.32</p></td><td><p>8.61</p></td><td><p>2.74</p></td><td><p>2.84</p></td><td><p>2.59</p></td><td><p>2.65</p></td><td><p>2.70</p></td></tr><tr><td><p>Mometasone Furoate</p></td><td><p>0.36</p></td><td><p>0.31</p></td><td><p>0.26</p></td><td><p>0.23</p></td><td><p>0.21</p></td><td><p>0.76</p></td><td><p>0.71</p></td><td><p>0.61</p></td><td><p>0.63</p></td><td><p>0.67</p></td></tr><tr><td><p>Montelukast</p></td><td><p>38.91</p></td><td><p>43.01</p></td><td><p>46.96</p></td><td><p>51.71</p></td><td><p>31.31</p></td><td><p>0.98</p></td><td><p>1.02</p></td><td><p>1.03</p></td><td><p>1.16</p></td><td><p>0.81</p></td></tr><tr><td><p>Omalizumab</p></td><td><p>0.00</p></td><td><p>0.01</p></td><td><p>0.03</p></td><td><p>0.15</p></td><td><p>0.12</p></td><td><p>5.97</p></td><td><p>9.22</p></td><td><p>12.16</p></td><td><p>14.65</p></td><td><p>17.86</p></td></tr><tr><td><p>Salbutamol</p></td><td><p>83.15</p></td><td><p>82.64</p></td><td><p>60.58</p></td><td><p>60.37</p></td><td><p>59.95</p></td><td><p>3.78</p></td><td><p>3.77</p></td><td><p>3.36</p></td><td><p>3.38</p></td><td><p>3.29</p></td></tr><tr><td><p>Salmeterol</p></td><td><p>48.80</p></td><td><p>45.16</p></td><td><p>41.87</p></td><td><p>36.72</p></td><td><p>34.04</p></td><td><p>0.87</p></td><td><p>0.74</p></td><td><p>0.59</p></td><td><p>0.53</p></td><td><p>0.47</p></td></tr><tr><td><p>Terbutaline Sulphate</p></td><td><p>8.61</p></td><td><p>8.20</p></td><td><p>7.61</p></td><td><p>7.43</p></td><td><p>7.18</p></td><td><p>0.18</p></td><td><p>0.16</p></td><td><p>0.14</p></td><td><p>0.14</p></td><td><p>0.15</p></td></tr><tr><td><p>Theophylline</p></td><td><p>2.18</p></td><td><p>2.17</p></td><td><p>2.15</p></td><td><p>2.22</p></td><td><p>2.26</p></td><td><p>0.12</p></td><td><p>0.11</p></td><td><p>0.11</p></td><td><p>0.11</p></td><td><p>0.11</p></td></tr><tr><td><p>Tiotropium</p></td><td><p>113.61</p></td><td><p>129.98</p></td><td><p>149.81</p></td><td><p>169.35</p></td><td><p>185.24</p></td><td><p>5.69</p></td><td><p>6.03</p></td><td><p>6.22</p></td><td><p>6.64</p></td><td><p>6.87</p></td></tr><tr><td><p>Zafirlukast</p></td><td><p>0.79</p></td><td><p>0.71</p></td><td><p>0.71</p></td><td><p>0.70</p></td><td><p>0.69</p></td><td><p>0.01</p></td><td><p>0.01</p></td><td><p>0.01</p></td><td><p>0.01</p></td><td><p>0.01</p></td></tr><tr><td><p>Other drugs<sup>2</sup></p></td><td><p>0.90</p></td><td><p>0.79</p></td><td><p>0.66</p></td><td><p>0.62</p></td><td><p>0.60</p></td><td><p>0.04</p></td><td><p>0.07</p></td><td><p>0.15</p></td><td><p>0.26</p></td><td><p>0.46</p></td></tr><tr><td><p>Total</p></td><td><p>911.6</p></td><td><p>952.3</p></td><td><p>968.5</p></td><td><p>1,007.5</p></td><td><p>1,018.3</p></td><td><p>40.3</p></td><td><p>43.8</p></td><td><p>45.0</p></td><td><p>49.0</p></td><td><p>52.4</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p><sup>1 </sup>Cost of drugs at NHS list price not taking account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.</p><p> </p><p><sup>2</sup> Other drugs include Azelastine/Fluticasone, Bambuterol Hydrochloride, Beclometasone/ Formoterol, Cromoglicic Acid, Fenoterol Hydrobromide, Fenoterol/Ipratropium Bromide, Fluticasone/ Formoterol, Nedocromil Sodium, Orciprenaline Sulfate and Sodium Cromoglicate.</p><p> </p><p>Source:</p><p> </p><p>Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)</p><p> </p><p>Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)</p><p> </p><p> </p><p> </p><p>Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of these drugs for conditions other than for asthma.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:13:01 answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

100885

	registered interest
	date	24/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Asthma: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much the Government has spent on the development of new drugs to treat the symptoms of asthma in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	uin	211885
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:29 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall